Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing.
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic drug monitoring and longitudinal treatment monitoring.
“Making our technology platform accessible to the pharma and biobanking industry will provide the opportunity for deeper clinical insights and improve stratification of patient data in clinical trials,” said Dr. Ali Tinazli, CEO of Lifespin GmbH. The comprehensive and quantitative metabolic profiling services will enable pharmaceutical companies in particular to perform a range of precision phenotyping of cell or animal models and patient cohorts.
Leveraging Lifespin’s Comprehensive Metabolic Database
Lifespin has built one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. Leveraging this resource can offer significant benefits to researchers in the pharma and biobank fields.
“The human and financial costs of failed drug candidates or drugs being recalled after launch can be extraordinary,” Tinazli said. “Our goal is to provide the pharma and biobank scientists with yet another powerful resource in their development toolbox, including our advanced algorithms and database, to enhance their earlier phase analysis and to help better identify the strengths and weaknesses of compounds in study during research through clinical trials.”
“Our proprietary platform enables quantitative and highly reproducible metabolic profiling with minimum time and low sample volume without the need for sample preparation,” said Dr. Michael Helou, Head of Product and Business Development at Lifespin. “The highly precise, accurate and cost-effective analysis will be a powerful add-on for quality control, drug discovery as well as monitoring at any stage of drug development. The unique metabolic signature will support pharma companies to come one step closer to personalized and precision medicine treating patients related to their individual reaction to drugs.”
